Ads
related to: ovarian cancer platinum resistant treatment
Search results
Results from the WOW.Com Content Network
Mirvetuximab soravtansine is indicated for the treatment of adults with folate receptor alpha (FRα) positive, platinum-resistant epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. [2] [5] [6] Recipients are selected for therapy based on an FDA ...
Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer - 32% objective response rate (ORR) in evaluable patients at the 5.2 mg/kg starting dose – the selected dose for randomized portion (Part 2) of ongoing registrational REFRαME-O1 trial -
Nuvectis Pharma, Inc. (NASDAQ:NVCT) stock is trading lower after the company reported data from the Phase 1b study evaluating NXP800 in patients with platinum-resistant ARID1a-mutated ovarian cancer.
If ovarian cancer recurs, it is considered partially platinum-sensitive or platinum-resistant, based on the time since the last recurrence treated with platins: partially platinum-sensitive cancers recurred 6–12 months after last treatment, and platinum-resistant cancers have an interval of less than 6 months.
Vintafolide is an investigational targeted cancer therapeutic currently under development by Endocyte and Merck & Co. [1] It is a small molecule drug conjugate consisting of a small molecule targeting the folate receptor, which is overexpressed on certain cancers, such as ovarian cancer, and a potent chemotherapy drug, vinblastine.
As PTX-200, triciribine is currently in a Phase Ib/II study in breast cancer [13]) and a Phase Ib trial in platinum resistant ovarian cancer. [14] These trials completed in 2020 and 2019 respectively without publishing data, suggesting negative results.
PTK7 is expressed by many tumors, including ovarian cancer, breast cancer, and non-small cell lung cancer. [5] Early clinical trial results show a 50% response rate in patients with triple negative breast cancer and an almost complete response in ovarian tumors resistant to platinum-based chemotherapies. [6]
This companion imaging agent identifies cells expressing the folate receptor, including cancer and inflammatory cells. [ 2 ] Etarfolatide is currently being investigated together with the corresponding small molecule drug conjugate (SMDC) vintafolide in a Phase 3 study in platinum-resistant ovarian cancer and in a Phase 2b study in non-small ...
Ads
related to: ovarian cancer platinum resistant treatment